The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approving an oral therapy to treat
myelofibrosis patients with moderate to severe anaemia.
Myelofibrosis is a rare blood cancer that affects the body's normal production of blood cells, and the affected patients are likely to develop anaemia over the
course of the disease.
British drugmaker GSK, the manufacturer of the oral therapy known as momelotinib, said that it can be used to treat "both newly diagnosed and previously treated
myelofibrosis patients."
The medicine helps address disease-related splenomegaly (enlarged spleen) or symptoms in adult patients who are Janus kinase (JAK) inhibitor naïve or have been
treated with ruxolitinib, as stated by the company.
Nina Mojas, Senior Vice President of Oncology Global Product Strategy at GSK, said that receiving the positive CHMP opinion "is a significant step in bringing
momelotinib to patients in the EU with this difficult-to-treat blood cancer."
GlaxoSmithKline on Wednesday (April 13) said it had agreed to buy US group Sierra Oncology, a specialist in medicines for rare forms of cancer, for $1.9 billion.
The purchase, worth the equivalent of £1.6 billion, aims to support the development of new medicines alongside Sierra's bone marrow cancer treatment Momelotinib.
The deal, set to be completed this year, represents a near 40-percent premium to Sierra's closing share price on Tuesday, GSK said in a statement.
Momelotinib could help address the "significant unmet medical needs" of patients with the blood cancer myelofibrosis and anaemia, said GSK chief commercial officer
Luke Miels.
"With this proposed acquisition, we have the opportunity to potentially bring meaningful new benefits to patients and further strengthen our portfolio of specialty
medicines," he added.